Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results for OREX
5.84
+0.06 (1.04%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.62 - 6.00
52 week 3.11 - 7.82
Open 5.80
Vol / Avg. 2.39M/4.04M
Mkt cap 719.29M
P/E     -
Div/yield     -
EPS -0.56
Shares 123.17M
Beta 2.39
Inst. own 88%
Dec 3, 2014
Orexigen Therapeutics Inc at Piper Jaffray Healthcare Conference - 12:30PM EST - Add to calendar
Nov 24, 2014
Orexigen Therapeutics Inc at Brean Capital's Life Sciences Summit Conference
Nov 11, 2014
Orexigen Therapeutics Inc at Credit Suisse Healthcare Conference - Webcast
Nov 10, 2014
Q3 2014 Orexigen Therapeutics Inc Earnings Release
Nov 10, 2014
Q3 2014 Orexigen Therapeutics Inc Earnings Call - Webcast
Sep 18, 2014
Orexigen Therapeutics Inc at Bank of America Merrill Lynch Global Healthcare Conference - Webcast
Sep 11, 2014
Orexigen Therapeutics Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 36.53% -2265.78%
Operating margin 42.26% -2251.98%
EBITD margin - -2249.24%
Return on average assets 30.62% -48.65%
Return on average equity 518.77% -132.40%
Employees 50 -
CDP Score - -

Address

Suite 200, 3344 N. Torrey Pines Court
LA JOLLA, CA 92037
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Joseph P. Hagan Acting Chief Financial Officer, Treasurer, Chief Business Officer
Age: 45
Bio & Compensation  - Reuters
Heather D. Turner Senior Vice President, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Senior Vice President, Head of Global Development
Age: 45
Bio & Compensation  - Reuters
Mark D. Booth Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 49
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Brian H. Dovey MBA Independent Director
Age: 72
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 49
Bio & Compensation  - Reuters